...
首页> 外文期刊>Artificial Organs >Zero Diffusive Sodium Balance in Hemodialysis Provided by an Algorithm-Based Electrolyte Balancing Controller: A Proof of Principle Clinical Study
【24h】

Zero Diffusive Sodium Balance in Hemodialysis Provided by an Algorithm-Based Electrolyte Balancing Controller: A Proof of Principle Clinical Study

机译:由算法的电解质平衡控制器提供的血液透析中零扩散钠平衡:原理临床研究证明

获取原文
获取原文并翻译 | 示例

摘要

Restoring and controlling fluid volume homeostasis is still a challenge in contemporary end-stage kidney disease patients treated by intermittent hemodialysis (HD) or hemodiafiltration (HDF). This primary target is achieved by ultrafiltration (dry weight probing) and control of intradialytic sodium transfer (dialysate-plasma Na gradient). The latter task is mostly ignored in clinical practice by applying a dialysate sodium prescription uniform for all patients of the dialysis center but unaligned to individual plasma sodium levels. Depending on the patient's natremia, a positive gradient gives rise to intradialytic diffusive sodium load and postdialytic thirst. On the contrary, a negative gradient may cause unwanted diffusive sodium removal and intradialytic symptoms. To overcome these challenges, a new conductivity-based electrolyte balancing algorithm embedded in a hemodialysis machine with the aim to achieve "zero diffusive sodium balance" in HD and online HDF treatments was tested in the form of a prospective clinical trial. The study comprised two phases: a first phase with a conventional fixed-sodium dialysate (standard care phase), followed by a phase with the electrolyte balancing control (EBC) module activated (controlled care phase). The results show a reduction in the variability of the intradialytic plasma sodium concentration shift, but it is overlain by a small but statistically significant increase in the mean plasma sodium levels. However, no clinical manifestations were observed. This sodium load can be explained by the design of the algorithm based on dialysate conductivity instead of sodium concentration. Furthermore, the increase in plasma sodium can be corrected by taking into account the potassium shift during the treatment. This study showed that the EBC module incorporated in the HD machine is able to automatically individualize the dialysate sodium to the patient's plasma sodium without measuring or calculating predialytic plasma levels from previous laboratory tests. This tool has the potential to facilitate fluid management, to control diffusive sodium flux, and to improve intradialytic tolerance in daily clinical practice.
机译:恢复和控制液体体积稳态仍是由间歇性血液透析(HD)或血液透析(HDF)治疗的当代末期肾病患者的挑战。通过超滤(干重探测)和对细胞发育性钠转移的控制(透析液 - 血浆Na梯度)来实现该主要靶标。通过对透析中心的所有患者施用透析液钠处方制服但未对个体血浆钠水平施加透析液钠处方制服,后者任务主要忽略了临床实践。根据患者的Natremia,阳性渐变会产生细胞发育性扩散钠载荷和后奈多渴。相反,阴性梯度可能导致不必要的扩散钠去除和细胞内症状。为了克服这些挑战,以预期临床试验的形式测试了一种嵌入式血液透析机中的新电导基电解质平衡算法,其目的是在高清和在线HDF治疗中获得“零扩散钠平衡”。该研究包括两相:具有常规固定钠透析酸钠(标准护理相)的第一相,然后用电解质平衡控制(EBC)模块激活(受控护理相)。结果表明,肠内血浆钠浓度变化的可变性降低,但它在平均血浆钠水平的小而统计学上显着增加。但是,没有观察到临床表现。该钠载荷可以通过基于透析酶导电率代替钠浓度的算法来解释算法。此外,通过考虑治疗期间的钾偏移,可以校正血浆钠的增加。该研究表明,在HD机器中结合的EBC模块能够将透析液钠自动地将患者的血浆钠胞质单独化,而不测量或计算来自先前的实验室测试的预氨基血浆水平。该工具有可能促进流体管理,控制扩散钠通量,并改善日常临床实践中的细胞内耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号